

A new tool for screening severe sleep apnea syndrome

Submission date 19/03/2019	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 22/03/2019	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 22/03/2019	Condition category Signs and Symptoms	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aim

Obstructive sleep apnea syndrome (OSAS) affects nearly one billion people worldwide. Specific screening tools are not available to identify OSAS in nocturnal polyuria (NP) populations. To develop a screening tool for detecting severe OSAS in patients presenting with NP.

Who can participate?

Men aged over 18 years who have nocturia due to nocturnal polyuria

What does the study involve?

This is a retrospective review of patients diagnosed with nocturia due to nocturnal polyuria and screened for obstructive sleep apnea syndrome between 2016 and 2018. The researchers gathered data about the collection of data, the characteristic of patients and their follow up. This is done to develop a screening tool for detecting severe OSAS in patients presenting with nocturnal polyuria.

What are the possible benefits and risks of participating?

There are no benefits or risks for participating.

Where is the study run from?

Clinique Pasteur, Toulouse

When is the study starting and how long is it expected to run for?

January 2016 to December 2018.

Who is funding the study?

The Clinique Pasteur

Who is the main contact?

Dr Vincent Misrai

vmisrai@clinique-pasteur.com

Contact information

Type(s)

Scientific

Contact name

Dr Vincent Misrai

ORCID ID

<http://orcid.org/0000-0003-2029-0650>

Contact details

Clinique Pasteur

45, avenue de Lombez

Toulouse

France

31300

+33562211652

vmisrai@clinique-pasteur.com

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number**ClinicalTrials.gov number**

Nil known

Secondary identifying numbers

2212434

Study information

Scientific Title

A tool for severe obstructive sleep apnea syndrome screening in patients with unexplained nocturnal polyuria

Study objectives

Obstructive sleep apnea syndrome (OSAS) affects nearly one billion people worldwide. Specific screening tools are not available to identify OSAS in nocturnal polyuria (NP) populations. Our aim was to develop a screening tool for detecting severe OSAS using a large single-institutional dataset of patients referred for nocturnal polyuria.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 17/01/2016, Commission nationale de l'informatique et des libertés (CNIL, 3 Place de Fontenoy, TSA 80715, 75334 PARIS CEDEX 07, France; +33(0)153732222), ref: 2212434

Study design

Prospective observational cohort study

Primary study design

Observational

Secondary study design

Cohort study

Study setting(s)

Hospital

Study type(s)

Screening

Participant information sheet

No participant information sheet available

Health condition(s) or problem(s) studied

Nocturia

Interventions

Medical records of patients diagnosed with nocturia due to nocturnal polyuria and screened for obstructive sleep apnea syndrome (OSAS) with a sleep study (overnight polygraphy) Patients diagnosed with severe OSAS were compared to a group of patients without OSAS or diagnosed with mild to moderate OSAS. Clinical predictive factors associated with severe OSAS were identified via logistic regression. A score combining the main predictors was created and evaluated.

Intervention Type

Other

Primary outcome measure

To design and validate a new "score" (the Clinique Pasteur score) to detect severe OSAS in patients with unexplained nocturnal polyuria.

Secondary outcome measures

To validate this "score" (internal validation)

Development of the score**Step 1: logistic regression model**

The first step in constructing the score was to perform a multivariate logistic regression analysis. All variables associated with severe OSAS according to a p value <0.2 in the logistic regression were selected. For continuous variables, the log-linearity assumption had to be fulfilled to ensure the validity of the model. If this assumption was not fulfilled, the continuous variable was categorized. The continuous variables included in the final model were age and BMI, and the assumption of log-linearity was not fulfilled. The thresholds chosen for the categorization of BMI were 25 kg/m² and 30 kg/m² according to anthropometric definition (normal/overweight /obese). The threshold for age (70 years) was much more arbitrary and was choose for sample size and powerful of the prediction reasons. The results of the model are expressed by means of

odd-ratio together with their 95% confidence intervals computed by Wald's methods. The performance was assessed by the rate of prediction error, the receiver operating characteristic (ROC) curve and a graphical illustration of the specificity/sensitivity of the model. The area under this curve (AUC) and its 95% confidence interval computed by bootstrap procedure (2000 replicates) indicated the predictive performances of the model. The internal validity of the model was investigated by splitting the database into two cohorts: a learning cohort (65% of the sample size) to create the model and a validation cohort (35% of the sample size) to assess. Individuals were randomly assigned to one of the cohorts. The predictive performance was assessed by the rate of prediction error and ROC curves.

Step 2: construction of the score

As the variables involved in the model were discrete, it was possible to construct a simplified score by choosing interquartile proportional values to rounded values of the logistic regression coefficients. This simplified score was constructed by using the connection between the values of the score and the predicted probabilities for a patient presenting with unexplained NP to have a severe OSAS. The choice of the cut-off score was made according to the plot of PPV and NPV as a function of the threshold.

Overall study start date

20/01/2016

Completion date

31/12/2018

Eligibility

Key inclusion criteria

1. Diagnosed with a nocturia due to nocturnal polyuria
2. Screened for sleep apnea syndrome with overnight polygraphy

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

200

Key exclusion criteria

1. Patients presenting with the following potential causes of nocturnal polyuria:
 - 1.1 Diabetes insipidus
 - 1.2 Uncontrolled diabetes mellitus (defined by a serum glucose level > 200 mg/dL)
 - 1.3 Severe renal impairment (defined by a glomerular filtration rate of <30 ml/min)
 - 1.4 Heart failure
 - 1.5 Oedematous state

Date of first enrolment

21/01/2016

Date of final enrolment

31/12/2018

Locations

Countries of recruitment

France

Study participating centre

Clinique Pasteur

45 avenue de Lombez

Toulouse

France

31300

Sponsor information

Organisation

Clinique Pasteur

Sponsor details

45 avenue de Lombez

Toulouse

France

31300

+33562213326

vmisrai@clinique-pasteur.com

Sponsor type

Hospital/treatment centre

ROR

<https://ror.org/03er61e50>

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal.

Intention to publish date

31/12/2019

Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date